1. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model
   Said Ahmed Bahwal et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef
2. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
   Alejandro Olivares-Hernández et al, 2021, Journal of Clinical Medicine CrossRef
3. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)
   Feng Xiong et al, 2023, Expert Review of Gastroenterology & Hepatology CrossRef
4. A general platform for efficient extracellular expression and purification of Fab from Escherichia coli
   Manyu Luo et al, 2019, Applied Microbiology and Biotechnology CrossRef
5. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
   Robert L. Ferris et al, 2018, Cancer Treatment Reviews CrossRef
6. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse
   Tadashi ASHIZAWA et al, 2019, Biomedical Research CrossRef
7. Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders
   Antonina Coppola et al, 2019, Journal of Clinical Medicine CrossRef
8. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
   Aohan Hou et al, 2020, Frontiers in Immunology CrossRef
9. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
   A. Mitsuhashi et al, 2018, Clinical and Translational Oncology CrossRef
10. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
    Qianquan Ma et al, 2018, Frontiers in Immunology CrossRef
11. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Yaqi Li et al, 2020, Immunology Letters CrossRef
12. Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells
    Ying Li et al, 2021, Aging CrossRef
13. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
    Rebekka Weber et al, 2018, Frontiers in Immunology CrossRef
14. Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
    Alba Martín-Moreno et al, 2020, Pharmaceutics CrossRef
15. Cutaneous melanoma: From pathogenesis to therapy (Review)
    Giulia Leonardi et al, 2018, International Journal of Oncology CrossRef
16. Cell Membrane Surface-Engineered Nanoparticles for Dermal Wound Healing and Melanoma (Regenerative Medicine and Cancer Therapy of Skin)
    Zainab Ahmadian et al, 2024, Cell Membrane Surface-Engineered Nanoparticles: Biomimetic Nanomaterials for Biomedical Applications CrossRef